Global marketing of lifesaving drugs: An analogical model

Journal of Consumer Marketing

Volumn 22, Issue 7, 2005, Pages 404-411

  Mascarenhas, Oswald A ^a   Kesavan, Ram ^a   Bernacchi, Michael ^a  

^a UNIVERSITY OF DETROIT MERCY   (United States)

Author keywords

Acquired immune deficiency syndrome; Developing countries; HIV; International marketing; Medical products

Indexed keywords

EID: 28844479404     PISSN: 07363761     EISSN: None     Source Type: Journal    
DOI: 10.1108/07363760510631147     Document Type: Article

References (29)

1. Ashcroft, R.E. (2001), "Affordable access to essential medication in developing countries: conflicts between ethical and economic imperatives", Journal of Medicine and Philosophy, Vol. 27 No. 2, pp. 179-95.
2. Calfee, J.E. and Bate, R. (2004), "Pharmaceuticals and the worldwide HIV epidemic: can stakeholder model work?", Journal of Public Policy and Marketing, Vol. 23 No. 2, pp. 140-52.
3. Challener, C. (2003), "Finding the bright spots in the vanishing Pharma Pipeline", Chemical Market Reporter, Vol. 262 No. 2, p. 4.
4. Danzon, P.M. (1997), "Price discrimination for pharmaceuticals: welfare effects in the US and the EU", International Journal of the Economics of Business, Vol. 4 No. 3, pp. 301-21.
5. Danzon, P.M. and Towse, A. (2003), "Differential pricing for pharmaceuticals: reconciling access, R&D and patents", International Journal of Healthcare Finance and Economics, Vol. 3, pp. 183-205.
6. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003), "The price of innovation: new estimates of drug development costs", Journal of Healthcare Economics, Vol. 22 No. 2, pp. 151-85.
7. Garrett, L. and Rosenstein, S. (2005), "Missed opportunities", Harvard International Review, Vol. 27 No. 1, pp. 64-70.
8. Gavetti, G. and Rivkin, J.W. (2005), "How strategists really think: tapping the power of analogy", Harvard Business Review, April, pp. 54-65.
9. Gayle, H. and Lange, J.M.A. (2004), "Seizing the opportunity to capitalize on the growing access to HIV treatment to expand HIV prevention", Lancet, Vol. 364, 3 July, pp. 6-7.
10. Gottlieb, M.S. (2001), "AIDS - past and future", New England Journal of Medicine, Vol. 344, 7 June, pp. 1788-91.
11. Grabowski, H.G., Vernon, J. and DiMasi, J.A. (2002), "Return on research and development for 1990s new drug introductions", Pharmacoeconomics, Vol. 20, Supplement 3, pp. 11-29.
12. Handy, C. (2002), "What's business for?", Harvard Business Review, Vol. 80 No. 12.
13. International AIDS Vaccine Initiative (2005), "Scientific blueprint 2004: accelerating global efforts in AIDS vaccine research and development" available at: www.iavi.org/pdf/ IAVIScientificBlueprint2004.pdf (accessed March 10, 2005).
14. Kennedy, C.R., Harris, F.H. and Lord, M. (2004), "Integrating public policy and public affairs in a pharmaceutical marketing program: the AIDS pandemic", Journal of Public Policy and Marketing, Vol. 23 No. 2, pp. 128-39.
15. Kim, W.C. and Mauborgne, R. (2004), "Blue ocean strategy", Harvard Business Review, Octobe, pp. 76-85.
16. Kremer, M. (2002), "Pharmaceuticals and the developing world", Journal of Economic Perspectives, Vol. 16, Fall, pp. 67-90.
17. Letelier, M.F., Flores, F. and Spinosa, C. (2003), "Developing productive customers in emerging markets", by Edward C. Green, California Management Review, Vol. 45 No. 4.
18. Low-Beer, D. (2004), "Review of rethinking AIDS prevention", Lancet, Vol. 364, July 3, pp. 19-20.
19. McGrath, R.G. and MacMillan, I.C. (2005), "Market busting: strategies for exceptional business growth", Harvard Business Review, March, pp. 80-91.
20. Nakashima, E. and Brown, D. (2004), "AIDS meeting focuses on prevention: Bangkok conference ends amid debate on progress and funding of methods", Washington Post, 17 July, p. A13.
21. Nierle, T. (2003), "Humanitarian medicine: one person at a time" available at: www.doctorswithoutborders.org/ publications/ar/i2003/ humanitarianmedicine.shtml.
22. Prahalad, C.K. (2004), "Why selling to the poor makes for good business sense", Fortune, Vol. 150 No. 10, pp. 70-2.
23. Prahalad, C.K. and Hammond, A. (2002), "Serving the world's poor, profitably", Harvard Business Review, Vol. 80 No. 9, pp. 48-9.
24. Rosen, S., Vincent, J.R., MacLeod, W., Fox, M. and Thea, D.M. (2003), "AIDS is your business", Harvard Business Review, February, pp. 81-7.
25. Slater, J. (2003), "India's drug makers emerge as important industry rivals", The Wall Street Journal, November 13, p. A3.
26. Tenet, G. (2003), "The worldwide threat in 2003: evolving dangers in a complex world", available at: www.odci.gov/ cia/pubaffairs/speeches/dci (accessed November 11, 2003).
27. UNAIDS (2004), 2004 Report on the Global AIDS Epidemic, UNAIDS, Geneva.
28. Vachani, S. and Smith, C.N. (2004), "Socially responsible pricing: lessons from the pricing of AIDS drugs in developing countries", California Management Review, Vol. 47 No. 1, pp. 117-45.
29. Zimmerman, R. (2001), "Glaxo to allow South African firm to produce and market its AIDS drugs", The Wall Street Journal, October 8.